Indeed, the AD treatment paradigm is now divided into two main approaches: targeting the T helper (Th) 2 pathway, especially the IL-4/13 axis, and targeting the JAK/STAT pathway. This evidence concerns the gene SOAT1 and Alzheimer disease.